In an interview with Bloomberg published yesterday, Sage’s CEO Jeff Jonas was quoted as saying his company was at the top of everyone’s buying list, sending its shares jumping.
But a few short hours later (and just before the end of after-hours trading), the chief rowed back on the M&A talk.
This comes as the company also got a share boost after its major depressive disorder candidate SAGE-217 recently hit its marks in a small, phase 2 test.
Bloomberg got an interview with Jonas about the data, where he said Sage was “on top of everyone’s M&A list,’’ and has been “hearing a great deal from a lot of companies,” an uncommon mantra from a biotech CEO, especially after a relatively small trial win, but with much more to be done.
But markets like these words, so cue its shares up by 9% in normal trading hours on the news. But later yesterday evening, the company released a statement trying to lower the tone of these comments.
“Dr. Jonas acknowledged the industry’s interest in the MDD data,” the brief update said. “Dr. Jonas’ statements did not imply that the company was in discussions with potential buyers […] Sage will have no further comment on these matters and as a policy does not comment on speculation regarding M&A activities.”
Its shares fell 1.2% afterhours, with its biggest dip coming after the release of this statement, and was down around 5% premarket this morning.
By Ben Adams
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
